Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

90.54 -1.02 (-1.11%)
Streaming Delayed Price Updated: 2:16 PM EST, Dec 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
74 75 Next >
News headline image
AstraZeneca Says Lynparza/Imfinzi Combo Shows Strong Clinical Benefit Vs. Chemotherapy In Endometrial Cancer ↗
AstraZeneca's latest analysis on Imfinzi plus chemotherapy followed by Imfinzi plus Lynparza in endometrial cancer. Improved secondary efficacy endpoints in patients with advanced or recurrent... 
Via Benzinga
News headline image
AstraZeneca caps patient out-of-pocket costs at $35 per month for its US inhaled respiratory portfolio
From AstraZeneca
Via Business Wire
News headline image
7 Mega-Cap Stocks That Can Turn $10,000 Into $1 Million ↗
These million dollar mega-cap stocks will continue to produce big winners in 2024 and beyond as they continue to rise. 
Via InvestorPlace
News headline image
Congressional Scrutiny Intensifies On Chinese Biotech Firms: WuXi AppTec Faces Biotech Exodus ↗
Amidst regulatory challenges, WuXi AppTec faces backlash from industry giants. Biotechnology Innovation Organization cuts ties, citing national security concerns. Shares plummet as U.S. bills target... 
Via Benzinga
News headline image
Check Out What Whales Are Doing With AZN ↗
 
Via Benzinga
News headline image
AstraZeneca Beefs Up Its Endocrine Disease Pipeline With Amolyt Pharma Deal Worth $1.05B ↗
AstraZeneca to acquire Amolyt Pharma for up to $1.05 billion, expanding rare disease pipeline with eneboparatide (AZP-3601), a Phase 3 investigational peptide for hypoparathyroidism. 
Via Benzinga
News headline image
Billionaire’s Biotech Bets: 3 Stocks Dominating Bill Gates’ Portfolio ↗
One of the primary features of Bill Gates biotech stocks is they are all working towards a cure for HIV and related illnesses. 
Via InvestorPlace
News headline image
What's Going On With Silence Therapeutics Stock Today? ↗
Silence Therapeutics reports narrower Q4 loss, data from zerlasiran study, and strengthened cash position. In March 2024, Mallinckrodt notified Silence that they will not pursue further development of... 
Via Benzinga
News headline image
AstraZeneca announces initiation of THARROS – a Phase III clinical trial investigating the potential of BREZTRI to improve cardiopulmonary outcomes in people with COPD
From AstraZeneca
Via Business Wire
News headline image
Top Wall Street Analysts Flag US Market Concentration Anxiety, Advise Investors To Adopt 'Barbell Approach' ↗
Goldman Sachs urges investors to diversify geographically due to high concentration in US tech stocks, with Japan, healthcare, and European GRANOLAS highlighted as promising markets. 
Via Benzinga
News headline image
Pharma Stock Roundup: Novo Nordisk's New Obesity Pill Data, Roche, AstraZeneca's Pipeline Updates ↗
This week, data from Novo Nordisk’s early-stage study on a new weight loss pill called amycretin showed that it could be more effective than Wegovy. Meanwhile, the FDA approved Johnson & Johnson's lung... 
Via Talk Markets
News headline image
Medicare's Ambitious Drug Price Negotiation Plan: President Joe Biden Calls To Expand Targeted Medicines To 50 Annually by 2029 ↗
Explore President Biden's plan to expand Medicare drug negotiations, targeting at least 50 drugs annually. Uncover the impact on pharmaceutical profits and the broader health-care policy proposals,... 
Via Benzinga
News headline image
Biden's State Of The Union: Grading His Results On Abortion Access, Drug Prices And Opium Epidemic ↗
As President Biden prepares for his State of the Union address, he will address issues such as Bidenomics, healthcare, and the US's role in the world. 
Via Benzinga
News headline image
Week In Review: Mabwell Sells Ex-China Rights To Rare Disease Therapy In $412 Million Deal ↗
Mabwell, a Shanghai-San Diego biotech, sold ex-China rights for 9MW3011 to Disc Medicine of Watertown, MA in a deal worth up to $412 million. Meanwhile, AstraZeneca has returned most of the global... 
Via Talk Markets
News headline image
Got $200? 2 Dividend Stocks to Buy and Hold Forever ↗
Trust these two real estate stocks to be attractively priced and proven performers. 
Via The Motley Fool
News headline image
2 Stocks That Could Turn $1,000 Into $2,500 in 5 Years ↗
It will take a lot, but this goal isn't out of reach for these stocks. 
Via The Motley Fool
News headline image
11 'Granolas' Stocks Outperform Magnificent 7 With Lower Volatility, Higher Yields ↗
A group of stocks, which Goldman Sachs dubbed the "Granolas," accounted for 50% of gains of the Stoxx Europe 600 Index for the past year. 
Via Benzinga
News headline image
3 Inflation-Resilient Stocks to Weather the Economic Turbulence ↗
These are the undervalued inflation-resilient stocks to buy as they represent companies that have strong fundamentals. 
Via InvestorPlace
News headline image
EXCLUSIVE: Vivani Medical Says Weight Loss/Diabetes Implant At Par With Novo Nordisk's Famed Injectable Wegovy/Ozempic, Animal Studies Shows ↗
Vivani Medical unveils preclinical data on NPM-115, a twice-yearly exenatide subdermal implant for weight loss. Achieving a 20% reduction in high-fat diet-induced obese mice, comparable to Novo... 
Via Benzinga
News headline image
Eli Lilly, Novo Nordisk's Strategies Against New Weight-Loss Drug Competitors ↗
Zealand Pharma's drug showed positive results in 83% of patients in Phase 2 trials for MASH, heating up the race for new obesity drugs and pushing the company's shares 30% higher. 
Via Benzinga
News headline image
MANDARA Phase III data published in New England Journal of Medicine show remission is an achievable goal in eosinophilic granulomatosis with polyangiitis (EGPA) with FASENRA
From AstraZeneca
Via Business Wire
News headline image
Move Over Magnificent 7, Say Hello to the GRANOLAS ↗
Dive into the compelling world of GRANOLAS stocks: Europe's elite players shaping the future of pharmaceuticals, tech, and consumer goods. 
Via InvestorPlace
News headline image
Why AstraZeneca Stock Is Trading Higher Tuesday ↗
FDA greenlights AstraZeneca's Tagrisso combo for advanced EGFRm NSCLC. FLAURA2 Phase 3 trial results reveal a 38% reduction in progression risk with Tagrisso plus chemo, outperforming monotherapy.... 
Via Benzinga
News headline image
Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated advanced nonsquamous non-small cell lung cancer
From AstraZeneca
Via Business Wire
News headline image
TAGRISSO® (osimertinib) demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial
From AstraZeneca
Via Business Wire
News headline image
Cruising For A Bruising ↗
We’re currently living in the soft landing, and it is pleasant indeed. But inflation numbers at the start of the year have put us on notice. Like the Magnificent Seven, hopes of a sustained soft... 
Via Talk Markets
Topics Economy
News headline image
Week In Review: LianBio To Close Operations; Will Pay $528 Million To Shareholders ↗
LianBio, a Princeton-Shanghai biotech, has decided to call it quits. LianBio plans to stop all of its operations by the end of 2024, and it will distribute a $4.80 dividend/share ($528 million) to its... 
Via Talk Markets
News headline image
TAGRISSO® (osimertinib) with the addition of chemotherapy approved in the US for patients with EGFR-mutated advanced lung cancer
From AstraZeneca
Via Business Wire
News headline image
7 Contrarian Biotech Stocks to Consider Amid Sector Weakness ↗
Although the healthcare innovation space has struggled recently, these contrarian biotech stocks now offer compelling discounts. 
Via InvestorPlace
News headline image
7 Must-Buy Pharma Stocks Amid the Weight Loss Drug Revolution ↗
Obesity drug sales boomed in 2023 and will continue in 2024. That could make these weight loss stocks even more attractive. 
Via InvestorPlace
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
74 75 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.